Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Cue Biopharma reported Q2 2026 revenue of $7.9 million, up from $3.0 million in the prior year, driven by a milestone payment from the Boehringer Ingelheim collaboration. The company recorded a net loss of $153.1 million, largely due to one-time non-cash charges of approximately $63.1 million and significant expenses related to the CUE-221 license agreement.
Key figures
- Revenue
- 7900000
- Guidance
- CUE-221 Phase 2 data anticipated by end of Q3 2026; CUE-401 Phase 1 initiation expected by end of 2026
- Net loss
- 153100000
- Ga expenses
- 46600000
- Rd expenses
- 49000000
- Cash balance q2
- 17400000
- Private placement proceeds
- 50000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.